Read about Endologix
in the news

Embrace the evidence.

The Latest:

One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)

See Release

All News


Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System

Endologix Announces that Lucas Buchanan Joins Board of Directors

Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease

Endologix Announces 24-Month Results of DETOUR- 2 Study at 2023 Vascular Annual Meeting

Endologix receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD.